<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04003103</url>
  </required_header>
  <id_info>
    <org_study_id>8591-016</org_study_id>
    <secondary_id>Merck Protocol Number</secondary_id>
    <nct_id>NCT04003103</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)</brief_title>
  <official_title>A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly
      doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of
      HIV-1 infection
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2019</start_date>
  <completion_date type="Anticipated">October 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with an adverse event</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 adverse event (AE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants who discontinued from study therapy</measure>
    <time_frame>Up to week 20</time_frame>
    <description>Percentage of participants who discontinued from study therapy due to an AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with a drug-related AE</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 drug-related AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with a serious adverse event</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 serious AE (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with a Grade 3 to 5 AE</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 Grade 3 (severe AE) to 5 (death) AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with a serious and drug-related AE</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 AE which is both serious and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with a Grade 3 to 5 and drug-related AE</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with at least 1 AE which is both Grade 3 (severe AE) to 5 (death) AE and drug-related</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants with an AE resulting in death</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants with an AE which results in death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of plasma islatravir</measure>
    <time_frame>Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.</time_frame>
    <description>Area under the concentration-time curve (AUC) from time 0 to 672 hours post-dose of plasma islatravir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of plasma islatravir</measure>
    <time_frame>Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.</time_frame>
    <description>Maximum concentration (Cmax) post-dose of plasma islatravir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of plasma islatravir</measure>
    <time_frame>Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.</time_frame>
    <description>Trough concentration (Ctrough) post-dose of plasma islatravir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of plasma islatravir</measure>
    <time_frame>Day 1 and Week 20, collect predose and 30-min postdose. On Day 2 collect ~24 hours after Day 1 dose. On Weeks 4, 8, 12 and 16, collect predose. Weeks 1, 2, 3, 21, 22, 23 and 24: collect at any time during the study visit.</time_frame>
    <description>Apparent terminal half-life (t1/2) post-dose of plasma islatravir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of islatravir-triphosphate in peripheral blood mononuclear cells</measure>
    <time_frame>Day 1, Day 2, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 21, 22, 23, 24, 25-26, 26-27, 28, 32, 36, 25-26, 26-27, 28, 32, 36, 44, 52, 60, and 68</time_frame>
    <description>AUC from time 0-672 hours post-dose of islatravir-triphosphate in peripheral blood mononuclear cells (PBMCs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of islatravir-triphosphate in PBMCs</measure>
    <time_frame>Day 1, Day 2, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 21, 22, 23, 24, 25-26, 26-27, 28, 32, 36, 25-26, 26-27, 28, 32, 36, 44, 52, 60, and 68</time_frame>
    <description>Maximum concentration (Cmax) post-dose of islatravir-triphosphate in PBMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration of islatravir-triphosphate in PBMCs</measure>
    <time_frame>Day 1, Day 2, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 21, 22, 23, 24, 25-26, 26-27, 28, 32, 36, 44, 52, 60, and 68</time_frame>
    <description>Trough concentration (Ctrough) post-dose of islatravir-triphosphate in PBMCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal half-life of islatravir-triphosphate in PBMCs</measure>
    <time_frame>Day 1, Day 2, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 21, 22, 23, 24, 25-26, 26-27, 28, 32, 36, 44, 52, 60, and 68</time_frame>
    <description>Apparent terminal half-life (t1/2) post-dose of islatravir-triphosphate in PBMCs</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Islatravir 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg islatravir + placebo for islatravir administered once monthly, orally in capsule form for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Islatravir 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg islatravir administered once monthly, orally in capsule form for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for islatravir administered once monthly, orally in capsule form for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islatravir</intervention_name>
    <description>Islatravir administered orally in capsule form once monthly for 24 weeks</description>
    <arm_group_label>Islatravir 120 mg</arm_group_label>
    <arm_group_label>Islatravir 60 mg</arm_group_label>
    <other_name>MK-8591</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for islatravir administered orally in capsule form once monthly for 24 weeks</description>
    <arm_group_label>Islatravir 60 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is in general good health with acceptable laboratory values at screening

          -  Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before
             randomization

          -  Has low risk of HIV infection, within 12 months prior to screening visit

          -  Use contraceptives consistent with local regulations

          -  Female is not pregnant or breastfeeding, and is not a woman of childbearing potential
             (WOCBP)

          -  A WOCBP is using an acceptable contraceptive method, or is abstinent from heterosexual
             intercourse as their preferred and usual lifestyle; or has a negative pregnancy test.

        Exclusion Criteria:

          -  Has hypersensitivity or other contraindication to any of the components of the study
             interventions as determined by the investigator

          -  Has an active diagnosis of hepatitis due to any cause

          -  Has a history of malignancy â‰¤5 years prior to signing informed consent except for
             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.

          -  Is taking or is anticipated to require systemic immunosuppressive therapy, immune
             modulators, or any prohibited therapies from 30 days prior to Day

             1 through the duration of the study.

          -  Is currently participating in or has participated in an interventional clinical study
             with an investigational compound or device within 30 days prior to Day1 through the
             duration of the study.

          -  Has previously been randomized in a study and received islatravir (MK-8591).

          -  Female is expecting to conceive or donate eggs at any time during the study

          -  Has QTc interval (using Fridericia correction) &gt;450 msec (for males) or &gt;460 msec (for
             females) or deemed clinically abnormal by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Centers of America, LLC ( Site 0007)</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-990-7649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine - Drug Development Unit ( Site 0002)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-287-7156</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Celerion, Inc. ( Site 0006)</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>402-437-6390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magee Womens Research Institute ( Site 0001)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>412-383-1313</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0017)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Jerusalem ( Site 0016)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226779374</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>JOSHA Research ( Site 0015)</name>
      <address>
        <city>Bloemfontein</city>
        <state>Free State</state>
        <zip>9300</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27514128160</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical HIV Research Unit CHRU ( Site 0014)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27112768800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emavundleni Vaccine Centre ( Site 0011)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7750</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27216505851</phone>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>4'-ethynyl-2-fluoro-2'-deoxyadenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

